Secarna Pharmaceuticals GmbH & Co. KG | Finanzwire

Basculer en Français

9472	Companies
185369	Keywords
117719	Articles
99261	Press releases

Headlines Articles Press releases Secarna Pharmaceuticals GmbH & Co. KG

Home
Companies
Secarna Pharmaceuticals GmbH & Co. KG

BRIEF

published on 10/23/2025 at 14:05, 1 month 12 days ago

Secarna Pharmaceuticals and Scenic Biotech Collaborate on Oligonucleotide Therapy

Drug Discovery Secarna Pharmaceuticals Genetic Disorders Scenic Biotech Oligonucleotide Therapy
PRESS RELEASE

published on 10/23/2025 at 14:00, 1 month 12 days ago

Secarna Pharmaceuticals enters discovery and co-development agreement with Scenic Biotech to develop disease-modifying oligonucleotide therapy against a novel drug target
Secarna Pharmaceuticals partners with Scenic Biotech to develop disease-modifying oligonucleotide therapy against novel drug target, leveraging expertise and synergies for new treatments

Secarna Pharmaceuticals Co-development Agreement Scenic Biotech Oligonucleotide Therapy Disease-modifying
BRIEF

published on 07/10/2025 at 09:05, 4 months 25 days ago

Secarna Pharmaceuticals and Vect-Horus Collaborate on RNA Therapeutics for CNS Disorders

Secarna Pharmaceuticals CNS Disorders Vect-Horus RNA Therapeutics Blood-brain Barrier
PRESS RELEASE

published on 07/10/2025 at 09:00, 4 months 25 days ago

Secarna Pharmaceuticals and Vect-Horus Announce Research Collaboration to Advance Systemic Delivery of RNA-Targeted Therapeutics for CNS Disorders
Secarna Pharmaceuticals and Vect-Horus announced a research collaboration to advance systemic delivery of RNA-targeted therapeutics for CNS disorders, combining expertise in RNA therapeutics and advanced delivery technologies

Secarna Pharmaceuticals Research Collaboration CNS Disorders Vect-Horus RNA-targeted Therapeutics
BRIEF

published on 05/23/2025 at 09:05, 6 months 12 days ago

Secarna Pharmaceuticals Unveils Promising SECN-15 Data at ASCO 2025

Cancer Therapy Clinical Trial Secarna Pharmaceuticals Antisense Oligonucleotide SECN-15
PRESS RELEASE

published on 05/23/2025 at 09:00, 6 months 12 days ago

Secarna Pharmaceuticals to present new data and clinical strategy for lead antisense oligonucleotide program SECN-15 at ASCO 2025
Secarna Pharmaceuticals to present new data and clinical strategy for SECN-15 at ASCO 2025. Targeting NRP1 with antisense oligonucleotides for solid cancers. Promising therapeutic approach

Secarna Pharmaceuticals Antisense Oligonucleotides SECN-15 ASCO 2025 Clinical Strategy
BRIEF

published on 05/12/2025 at 14:05, 6 months 23 days ago

Secarna Pharmaceuticals and Curie.Bio Sign Research Agreement

Drug Discovery Biopharmaceutical Collaboration Oligonucleotide Therapeutics Research Agreement AI-empowered Platform
PRESS RELEASE

published on 05/12/2025 at 14:00, 6 months 23 days ago

Secarna Pharmaceuticals and Curie.Bio Portfolio Company Enter into Research and Option Agreement
Secarna Pharmaceuticals and Curie.Bio Portfolio Company signed a research and option agreement to accelerate the discovery of novel oligonucleotide therapies

Research Option Agreement Secarna Pharmaceuticals Curie.Bio Oligonucleotide Therapies
BRIEF

published on 04/28/2025 at 14:35, 7 months 6 days ago

Prof. Dr. Vignali Joins Secarna Pharmaceuticals' Scientific Board

Scientific Advisory Board Immuno-oncology Secarna Pharmaceuticals SECN-15 Prof. Dr. Vignali
PRESS RELEASE

published on 04/28/2025 at 14:30, 7 months 6 days ago

Secarna Pharmaceuticals adds leading expert to Scientific Advisory Board with appointment of Prof. Dr. Vignali
Secarna Pharmaceuticals appoints Prof. Dr. Dario Vignali to Scientific Advisory Board, enhancing expertise in oncology research and immunotherapy strategies for solid tumors

Scientific Advisory Board Immunotherapy Oncology Research Secarna Pharmaceuticals Prof. Dr. Dario Vignali

Accesswire

Published on 12/05/2025 at 02:35, 2 hours 46 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 2 hours 51 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 4 hours 21 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 6 hours 16 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 6 hours 21 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 03:30, 1 hour 50 minutes ago

CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 5 hours 30 minutes ago

EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 8 hours 55 minutes ago

Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 9 hours 6 minutes ago

Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 10 hours 10 minutes ago

SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance

Les Echos

Published on 12/04/2025 at 18:00, 11 hours 21 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 11 hours 36 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 11 hours 37 minutes ago

Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 22 hours 20 minutes ago

bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 11 hours ago

Declaration of voting rights at the end of November 2025

View all LES ECHOS COMFI WIRE